Your browser is no longer supported. Please, upgrade your browser.
Denali Therapeutics Inc.
Index- P/E- EPS (ttm)-2.21 Insider Own0.10% Shs Outstand107.49M Perf Week-8.75%
Market Cap8.08B Forward P/E- EPS next Y-1.98 Insider Trans-94.21% Shs Float98.81M Perf Month-10.82%
Income-227.80M PEG- EPS next Q0.00 Inst Own78.70% Short Float8.70% Perf Quarter69.17%
Sales23.50M P/S344.02 EPS this Y-428.30% Inst Trans0.22% Short Ratio11.72 Perf Half Y175.79%
Book/sh8.21 P/B8.90 EPS next Y-25.30% ROA-30.70% Target Price65.60 Perf Year230.30%
Cash/sh8.68 P/C8.41 EPS next 5Y- ROE-39.20% 52W Range12.39 - 93.94 Perf YTD-12.81%
Dividend- P/FCF- EPS past 5Y- ROI-53.90% 52W High-22.26% Beta-
Dividend %- Quick Ratio9.20 Sales past 5Y- Gross Margin- 52W Low489.43% ATR5.43
Employees281 Current Ratio9.20 Sales Q/Q-30.90% Oper. Margin- RSI (14)45.94 Volatility5.16% 7.58%
OptionableYes Debt/Eq0.00 EPS Q/Q-12.30% Profit Margin- Rel Volume0.94 Prev Close73.99
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume733.98K Price73.03
Recom2.20 SMA20-9.64% SMA502.16% SMA20083.83% Volume691,839 Change-1.30%
Nov-11-20Reiterated H.C. Wainwright Buy $65 → $80
Oct-16-20Downgrade BTIG Research Buy → Neutral
Sep-14-20Resumed JP Morgan Overweight $35
Aug-20-20Reiterated H.C. Wainwright Buy $28 → $45
Mar-13-20Upgrade Evercore ISI In-line → Outperform $20
Feb-28-20Upgrade Wedbush Neutral → Outperform $24
Feb-24-20Initiated Jefferies Buy $35
Feb-19-20Initiated Stifel Hold $26
Jan-27-20Upgrade Goldman Neutral → Buy $20 → $37
Sep-26-19Initiated Wedbush Neutral $19
Sep-13-19Initiated Nomura Buy
Aug-09-19Initiated BTIG Research Buy $30
Jun-26-19Initiated H.C. Wainwright Buy $28
Nov-15-18Initiated Cantor Fitzgerald Overweight $25
Nov-12-18Initiated Janney Buy
Mar-12-18Downgrade Evercore ISI Outperform → In-line
Jan-02-18Initiated Morgan Stanley Overweight
Jan-02-18Initiated JP Morgan Overweight $24
Jan-02-18Initiated Goldman Neutral $19
Jan-02-18Initiated Evercore ISI Outperform $23
Jan-11-21 08:30AM  
Jan-08-21 08:30AM  
Dec-23-20 03:33PM  
Dec-22-20 09:48AM  
Nov-18-20 09:36AM  
Nov-13-20 08:35AM  
Nov-12-20 11:18AM  
Nov-10-20 07:30AM  
Nov-05-20 04:01PM  
Oct-21-20 02:00PM  
Oct-18-20 11:00AM  
Oct-15-20 08:00AM  
Oct-07-20 08:30AM  
Oct-05-20 12:01PM  
Sep-30-20 09:00AM  
Sep-24-20 11:46AM  
Aug-18-20 11:37AM  
Aug-07-20 05:45PM  
Aug-06-20 04:19PM  
Jul-29-20 09:00AM  
Jul-28-20 12:32PM  
Jul-07-20 08:00AM  
Jun-28-20 07:06PM  
Jun-10-20 02:03PM  
Jun-09-20 04:30PM  
May-28-20 11:21AM  
May-27-20 04:30PM  
May-21-20 12:00PM  
May-10-20 09:18AM  
May-07-20 08:20PM  
May-06-20 12:30PM  
Apr-15-20 02:49PM  
Apr-09-20 06:08PM  
Apr-02-20 04:30PM  
Feb-29-20 08:47AM  
Feb-27-20 05:55PM  
Feb-17-20 10:06AM  
Feb-14-20 03:00PM  
Feb-07-20 11:30AM  
Feb-03-20 11:11AM  
Jan-31-20 08:42PM  
Jan-30-20 11:10AM  
Jan-29-20 11:11AM  
Jan-28-20 08:58PM  
Jan-27-20 04:10PM  
Jan-23-20 09:34AM  
Jan-22-20 10:00AM  
Jan-16-20 09:52AM  
Jan-15-20 09:36AM  
Jan-14-20 10:03AM  
Dec-31-19 11:01AM  
Dec-19-19 08:00AM  
Dec-17-19 04:06PM  
Dec-03-19 08:58AM  
Nov-06-19 07:25PM  
Oct-27-19 11:08AM  
Sep-04-19 09:00AM  
Aug-06-19 08:05PM  
Aug-05-19 09:00AM  
Aug-01-19 10:33AM  
Jul-04-19 06:03AM  
Jun-29-19 06:27PM  
Jun-12-19 10:30AM  
Jun-11-19 09:00AM  
May-08-19 08:05PM  
May-03-19 10:30AM  
May-01-19 05:43PM  
Apr-30-19 02:52PM  
Apr-15-19 03:00PM  
Apr-10-19 10:03AM  
Apr-02-19 02:46PM  
Mar-14-19 02:42PM  
Mar-12-19 10:35AM  
Feb-19-19 07:55AM  
Feb-15-19 09:00AM  
Jan-30-19 09:49AM  
Jan-08-19 09:00AM  
Dec-10-18 09:00AM  
Dec-08-18 10:02AM  
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Further, it has various seed programs under the research, discovery, and preclinical stages of development. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schuth Alexander O.COO and SecretaryJan 04Sale74.9570,0005,246,408544,562Jan 06 06:50 PM
Watts Ryan J.President and CEOJan 04Sale74.9688,3346,621,7822,322,978Jan 06 06:49 PM
Schenkein David PDirectorDec 21Sale90.015,000450,02726,232Dec 23 09:52 PM
Schenkein David PDirectorDec 21Sale90.0625,0002,251,5550Dec 23 09:52 PM
BRATTON DOUGLAS K10% OwnerDec 14Sale80.3817,8251,432,842383,411Dec 15 04:47 PM
BRATTON DOUGLAS K10% OwnerDec 11Sale80.0546,7993,746,442401,236Dec 15 04:47 PM
Schenkein David PDirectorNov 12Sale70.0530,0002,101,59025,000Nov 13 05:13 PM
Schenkein David PDirectorNov 10Sale60.0310,000600,31055,000Nov 12 04:21 PM
Schenkein David PDirectorNov 04Sale50.1810,000501,83065,000Nov 06 05:53 PM
Ho CaroleChief Medical OfficerOct 09Option Exercise5.2830,000158,400196,617Oct 13 06:45 PM
Ho CaroleChief Medical OfficerOct 09Sale41.2230,0001,236,614166,617Oct 13 06:45 PM
Ho CaroleChief Medical OfficerOct 08Option Exercise5.2822,906120,944189,523Oct 13 06:45 PM
Ho CaroleChief Medical OfficerOct 08Sale40.1222,906918,989166,617Oct 13 06:45 PM
Ho CaroleChief Medical OfficerSep 10Sale31.003,689114,359165,141Sep 14 09:38 PM
BRATTON DOUGLAS K10% OwnerAug 12Sale31.651,443,24745,678,76812,201,634Aug 14 04:50 PM
BRATTON DOUGLAS K10% OwnerJun 30Sale24.0145,3451,088,601448,035Jun 30 07:17 PM
BRATTON DOUGLAS K10% OwnerJun 29Sale24.0182,5781,982,373493,380Jun 30 07:17 PM
BRATTON DOUGLAS K10% OwnerJun 26Sale23.94122,0772,922,078575,958Jun 30 07:17 PM
BRATTON DOUGLAS K10% OwnerJun 23Sale25.7720,024515,969698,035Jun 23 05:41 PM
BRATTON DOUGLAS K10% OwnerJun 22Sale24.7890,0562,231,902718,059Jun 23 05:41 PM
BRATTON DOUGLAS K10% OwnerJun 19Sale24.54144,9203,556,503808,115Jun 23 05:41 PM
Tessier-Lavigne MarcDirectorJun 16Sale26.10400,00010,440,0002,739,043Jun 18 09:41 PM
BRATTON DOUGLAS K10% OwnerJun 05Sale25.751,922,85549,513,51613,644,881Jun 09 04:10 PM
Krognes Steve E.CFO and TreasurerMar 30Sale19.481,42827,8171,006,488Apr 01 06:19 PM
Schuth Alexander O.COO and SecretaryMar 30Sale19.491,42727,81228,662Apr 01 06:19 PM
Watts Ryan J.President and CEOMar 30Sale19.484,80793,64022,013Apr 01 06:17 PM
Ho CaroleChief Medical OfficerMar 30Sale19.481,42827,8172,822Apr 01 06:18 PM
BRATTON DOUGLAS K10% OwnerFeb 26Sale20.253,894,76478,868,97115,567,736Feb 28 04:25 PM